1. Peña AS
    ¿Dónde están nuestros conocimientos sobre la genetic de la enfermedad inflamatoria crónica intestinal (EICC)?
    Enfermedad Inflamatoria intestinal al día (publicación de Geteccu para formación continuada) 2009;8:3-14
  2. Hadithi M, Mulder CJJ, Stam F, Azizi J, Crusius JBA, Peña AS, Stehouwer CDA, Smulders YM.
    Effect of B vitamin supplementation on plasma homocysteine levels in celiac disease.
    World J Gastroenterol 2009;15:955-60.
  3. Wouters J, Weijerman ME, van Furth AM, Schreurs MW, Crusius JB, von Blomberg BM, de Baaij LR, Broers CJ, Gemke RJ.
    Prospective human leukocyte antigen, endomysium immunoglobulin A antibodies, and transglutaminase antibodies testing for celiac disease in children with Down Syndrome.
    J Pediatr 2009;154:239-42.
  4. Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA, Verspaget HW, de Jong DJ, van der Woude CJ, Oldenburg B, Linskens RK, Festen EA, van der Steege G, Hommes DW, Crusius JB, Wijmenga C, Nolte IM, Dijkstra G.
    Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort.
    Gut 2009;58:388-95.
  5. de Vries HJ, Smelov V, Middelburg JG, Pleijster J, Speksnijder AG, Morre SA.
    Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment.
    Clin Infect Dis 2009;48:53-6.
  6. Nicu EA, Laine ML, Morre SA, Van der Velden U, Loos BG.
    Soluble CD14 in periodontitis.
    Innate Immun 2009;15:121-8.
  7. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morre SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, Netea MG.
    Human dectin-1 deficiency and mucocutaneous fungal infections.
    N Engl J Med 2009;361(18):1760-7
  8. Morre SA, Karimi O, Ouburg S.
    Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics.
    FEMS Immunol Med Microbiol 2009;55:140-53.
  9. van Winsen LML, Manenschijn L, van Rossum EFC, Crusius JBA, Koper JW, Polman CH, Uitdehaag BMJ.
    A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis.
    J Clin Endocrinol Metabol 2009; 94:2110-14.
  10. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Wolbink GJ, de Vries N, Tak PP, Dijkmans BA, Crusius JBA, van der Horst- Bruinsma IE.
    Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms
    Arthritis Rheum 2009;60:2541-2.
  11. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Burtt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Kurreeman FA, Lee AT, Liu X, Li Y, Martin P, Morgan AW, Padyukov L, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P, Altshuler D, Karlson EW, Toes RE, de Vries N, Begovich AB, Siminovitch KA, Worthington J, Klareskog L, Gregersen PK, Daly MJ, Plenge RM.
    Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.
    Nat Genet 2009; 41:1313-8.
  12. Sombekke MH, Lukas C, Crusius JBA, Tejedor D, Killestein J, Arteta D, Martínez A, Uitdehaag BMJ, Knol DL, Peña AS, Geurts JJG, De Jager PL, Barkhof F, Vrenken H, Polman CH.
    HLA-DRB1*1501 and spinal cord MRI lesions in Multiple Sclerosis.
    Arch Neurol 2009;66:1531-36.
  13. de Vries HS, Plantinga TS, van Krieken JH, Stienstra R, van Bodegraven AA, Festen EAM, Weersma RK, Crusius JBA, Linskens RK, Joosten LAB, Netea MG, de Jong DJ.
    Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease.
    PloS ONE 2009;4(11):e7818.
  14. Morré SA, Peña AS.
    An integrated approach to the understanding of Chlamydia infections: Introduction to the 2009 update.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:3-5.
  15. Morré SA, Ouburg S, Peña AS, Brand A.
    The EU FP6 EpiGenChlamydia Consortium: contribution of molecular epidemiology and host-pathogen genomics to understanding Chlamydia trachomatis-related disease.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:7-13.
  16. Lyons JM, Ouburg S, Morré SA.
    An integrated approach to Chlamydia trachomatis infection: the ICTI Consortium, an update.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:15-23.
  17. Smelov V, Quint KD, Pleijster J, Savelkoul PHM, Shalepo K, Shipitsyna E, Domeika M, Gorelov A, Savicheva A, Quint WGV, de Vries HJC, Ouburg S, Morré SA.
    Chlamydia trachomatis serovar distributions in Russian men and women: a comparison with Dutch serovar distributions.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:33-8.
  18. Lyons JM, Igietseme JU, Black CM, Morré SA.
    Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:51-9.
  19. Karimi O, Ouburg S, de Vries HJC, Peña AS, Pleijster J, Land JA, Morré SA.
    TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:67-74.
  20. den Hartog JE, Lyons JM, Ouburg S, Fennema JSA, de Vries HJC, Bruggeman CA, Ito JI, Peña AS, Land JA, Morré SA.
    TLR4 in Chlamydia trachomatis infections: knockout mice, STD patients and women with tubal factor subfertility.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:75-82.
  21. Ouburg S, Lyons JM, Land JA, den Hartog JE, Fennema JSA, de Vries HJC, Bruggeman CA, Ito JI, Peña AS,Lundberg PSJ, Morré SA.
    TLR9 KO mice, haplotypes and CPG indices in Chlamydia trachomatis infection.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:83-93.
  22. Wang W, Stassen FR, Surcel HM, Öhman H, Tiitinen A, Paavonen J, de Vries HJC, Heijmans R, Pleijster J, Morré SA,Ouburg S.
    Analyses of polymorphisms in the inflammasome-associated NLRP3 and miRNA-146A genes in the susceptibility to and tubal pathology of Chlamydia trachomatis infection.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:95-103.
  23. Peña AS, Karimi O, Crusius JBA.
    A new avenue to investigate: the autophagic process. From Crohn’s disease to Chlamydia.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:113-7
  24. Lyons JM, Morré SA, Land JA.
    Aspects of reproductive biology that influence the distribution and spread of Chlamydia trachomatis within the female genital tract: a new paradigm.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:119-24.
  25. Verweij SP, Bax CJ, Quint KD, Quint WGV, van Leeuwen AP, Peters RPH, Oostvogel PM, Mutsaers JA, Dörr PJ, Pleijster J, Ouburg S, Morré SA.
    Significantly higher serologic responses of Chlamydia trachomatis B group serovars versus C and I serogroups.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:135-40
  26. Rabasseda X, Morré SA, Ouburg S.
    Bioinformatic approaches to the study of Chlamydial diseases.
    Drugs Today (Barc) 2009 Nov;45 Suppl B:173-87.
  27. Dean D, Bruno WJ, Wan R, Gomes JP, Devignot S, Mehari T, de Vries HJ,Morré  SAM, Myers G, Read TD, Spratt BG.
    Predicting phenotype and emerging strains among Chlamydia trachomatis infections.
    Emerg Infect Dis 2009;15(9):1385-94